A Switch in Hepatic Cortisol Metabolism across the Spectrum of Non Alcoholic Fatty Liver Disease
Open accessThe DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
CONTEXT: Non alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of the metabolic syndrome. NAFLD represents a spectrum of liver disease ranging from reversible hepatic steatosis, to non alcoholic steato-hepatitis (NASH) and cirrhosis. The potential role of glucocorticoids (GC) in the pathogenesis of NAFLD is highlighted in patients with GC excess, Cushing's syndrome, who develop central adiposity, insulin resistance and in 20% of cases, NAFLD. Although in most cases of NAFLD, circulating cortisol levels are normal, hepatic cortisol availability is controlled by enzymes that regenerate cortisol (F) from inactive cortisone (E) (11β-hydroxysteroid dehydrogenase type 1, 11β-HSD1), or inactivate cortisol through A-ring metabolism (5α- and 5β-reductase, 5αR and 5βR). OBJECTIVE AND METHODS: In vitro studies defined 11β-HSD1 expression in normal and NASH liver samples. We then characterised hepatic cortisol metabolism in 16 patients with histologically proven NAFLD compared to 32 obese controls using gas chromatographic analysis of 24 hour urine collection and plasma cortisol generation profile following oral cortisone. RESULTS: In patients with steatosis 5αR activity was increased, with a decrease in hepatic 11β-HSD1 activity. Total cortisol metabolites were increased in this group consistent with increased GC production rate. In contrast, in patients with NASH, 11β-HSD1 activity was increased both in comparison to patients with steatosis, and controls. Endorsing these findings, 11β-HSD1 mRNA and immunostaining was markedly increased in NASH patients in peri septal hepatocytes and within CD68 positive macrophages within inflamed cirrhotic septa. CONCLUSION: Patients with hepatic steatosis have increased clearance and decreased hepatic regeneration of cortisol and we propose that this may represent a protective mechanism to decrease local GC availability to preserve hepatic metabolic phenotype. With progression to NASH, increased 11β-HSD1 activity and consequent cortisol regeneration may serve to limit hepatic inflammation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Decreased insulin sensitivity, independent of body adipose mass and hepatic steatosis, also alters cortisol kinetics, resulting in increased cortisol clearance87,88.”
From Management challenges and therapeutic advances in congenital adrenal hyperplasia (2022) · cites this paper as [87]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4
LAEMMLI, U. K. (1970) · Nature · doi:10.1038/227680a0 · Cited by 249,961
Raza, H., John, A., & Nemmar, A. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350087 · Cited by 47,221
Obesity is associated with macrophage accumulation in adipose tissue
Weisberg, S. P., McCann, D., Desai, M., Rosenbaum, M., Leibel, R. L., & Ferrante, A. W. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200319246 · Cited by 10,041 · cited 1×
“Adipose tissue insulin resistance may occur in obesity in part through the infiltration of macrophages which release pro inflammatory cytokines such as TNFa, IL-6 and IL1b [41].”
BackgroundKim, H. J., Park, S. Y., Choi, Y. J., Han, S. J., Lee, K. W., & Kim, D. J. (2013) · Hormone Research in Paediatrics · doi:10.1159/000348848 · Cited by 3,048
Local and systemic insulin resistance resulting from hepatic activation of IKK-β and NF-κB
Cai, D., Yuan, M., Frantz, D. F., Melendez, P. A., Hansen, L., Lee, J., & Shoelson, S. E. (2005) · Nature Medicine · doi:10.1038/nm1166 · Cited by 2,245
A transgenic model of visceral obesity and the metabolic syndrome
Masuzaki, H., Paterson, J., Shinyama, H., Morton, N. M., Mullins, J. J., Seckl, J. R., & Flier, J. S. (2001) · Science · doi:10.1126/science.1066285 · Cited by 1,766 · cited 1×
“Conversely recombinant mice with global deletion of 11b-HSD1 are protected from many of these features including hepatic steatosis [24,25].”
BackgroundFeldstein, A. E., Werneburg, N. W., Canbay, A., Guicciardi, M. E., Bronk, S. F., Rydzewski, R., Burgart, L. J., & Gores, G. J. (2004) · Hepatology · doi:10.1002/hep.20283 · Cited by 834
Non-alcoholic fatty liver disease: The mist gradually clears
de Alwis, N. M. W., & Day, C. P. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2008.01.009 · Cited by 603 · cited 2×
“However, the presence of fibrosis or inflammation at diagnosis is associated with a risk of developing NASH cirrhosis of up to 50% in a two year period [1].”
BackgroundTissue effects of glucocorticoids
Baxter, J. D., & Forsham, P. H. (1972) · The American Journal of Medicine · doi:10.1016/0002-9343(72)90154-4 · Cited by 503 · cited 1×
“Glucocorticoids promote steatosis by directly stimulating hepatic de novo lipogenesis and free fatty acid (FFA) utilization [5– 7], and by promoting lipolysis within omental fat, resulting in increased portal FFA delivery to the liver [8].”
BackgroundAssessment of abdominal fat content by computed tomography
Borkan, G., Gerzof, S., Robbins, A., Hults, D., Silbert, C., & Silbert, J. (1982) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/36.1.172 · Cited by 491 · cited 1×
“Fat pixels and therefore fat area were identified with threshold attenuation values between 250 to 2250 hounsfield units as described previously [16].”
Method
Cited by
Depression and obesity: evidence of shared biological mechanisms
Milaneschi, Y., Simmons, W. K., van Rossum, E. F. C., & Penninx, B. W. (2019) · Molecular Psychiatry · doi:10.1038/s41380-018-0017-5 · Cited by 1,073
Stress and Obesity: Are There More Susceptible Individuals?
van der Valk, E. S., Savas, M., & van Rossum, E. F. C. (2018) · Current Obesity Reports · doi:10.1007/s13679-018-0306-y · Cited by 402
Mechanisms of Glucocorticoid-Induced Insulin Resistance
Geer, E. B., Islam, J., & Buettner, C. (2014) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2013.10.005 · Cited by 392
Hutchison, A. L., Tavaglione, F., Romeo, S., & Charlton, M. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.08.030 · Cited by 250
Hepatic lipid accumulation: cause and consequence of dysregulated glucoregulatory hormones
Geisler, C. E., & Renquist, B. J. (2017) · Journal of Endocrinology · doi:10.1530/joe-16-0513 · Cited by 191
11β-hydroxysteroid dehydrogenase 1: translational and therapeutic aspects
Gathercole, L. L., Lavery, G. G., Morgan, S. A., Cooper, M. S., Sinclair, A. J., Tomlinson, J. W., & Stewart, P. M. (2013) · Endocrine Reviews · doi:10.1210/er.2012-1050 · Cited by 196
Self-citationGlucocorticoids and non-alcoholic fatty liver disease
Woods, C. P., Hazlehurst, J. M., & Tomlinson, J. W. (2015) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2015.07.020 · Cited by 171
“15 16 17 Glucocorticoid Receptor and NAFLD 18 19 There is a growing body of evidence for the role of the glucocorticoid receptor 20 (GR) in the pathogenesis of NAFLD/NASH.”
BackgroundResultInfluentialSelf-citationJanssen, J. A. M. J. L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158178 · Cited by 180
Emerging Liver–Kidney Interactions in Nonalcoholic Fatty Liver Disease
Musso, G., Cassader, M., Cohney, S. J., Pinach, S., Saba, F., & Gambino, R. (2015) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2015.08.005 · Cited by 146
“In NAFLD patients, hepatic and adipose tissue 11bHSD1 is upregulated and parallels the severity of hepatic inflammation [130,131].”
Management challenges and therapeutic advances in congenital adrenal hyperplasia
Mallappa, A., & Merke, D. P. (2022) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00655-w · Cited by 113
The Role and Mechanism of Oxidative Stress and Nuclear Receptors in the Development of NAFLD
Hong, T., Chen, Y., Li, X., & Lü, Y. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/6889533 · Cited by 123
“Elevated in NAFLD but reduced in NASH, 11β-HSD1 has versatile roles in lipid metabolism and GCrelated anti-inflammatory effects [113].”
BackgroundMechanisms in endocrinology: Non-alcoholic fatty liver disease in common endocrine disorders
Hazlehurst, J. M., & Tomlinson, J. W. (2013) · European Journal of Endocrinology · doi:10.1530/eje-13-0296 · Cited by 97
Self-citationLivingstone, D. E. W., Barat, P., Di Rollo, E. M., Rees, G. A., Weldin, B. A., Rog-Zielinska, E. A., MacFarlane, D. P., Walker, B. R., & Andrew, R. (2015) · Diabetes · doi:10.2337/db14-0249 · Cited by 100
Eicosanoids in Metabolic Syndrome
Hardwick, J. P., Eckman, K., Lee, Y., Abdelmegeed, M. A., Esterle, A. R., Chilian, W. M., Chiang, J. Y. L., & Song, B. (2013) · Advances in pharmacology · doi:10.1016/b978-0-12-404717-4.00005-6 · Cited by 105
“PPARα also interacts with the GR that mediates an increase in cortisol levels, which that is believed to be responsible for hyperinsulinemia observed in sepsis (Ahmed et al., 2012).”
BackgroundEndocrine causes of nonalcoholic fatty liver disease
Marino, L., & Jornayvaz, F. R. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i39.11053 · Cited by 100
Dowman, J. K., Hopkins, L. J., Reynolds, G. M., Armstrong, M. J., Nasiri, M., Nikolaou, N., van Houten, E. L. A. F., Visser, J. A., Morgan, S. A., Lavery, G. G., et al. (2013) · Endocrinology · doi:10.1210/en.2013-1592 · Cited by 82
Self-citationTarantino, G. (2013) · World Journal of Gastroenterology · doi:10.3748/wjg.v19.i40.6735 · Cited by 82
Pathophysiology of NASH in endocrine diseases
Gariani, K., & Jornayvaz, F. R. (2021) · Endocrine Connections · doi:10.1530/ec-20-0490 · Cited by 85
SETDB2 Links Glucocorticoid to Lipid Metabolism through Insig2a Regulation
Roqueta‐Rivera, M., Esquejo, R. M., Phelan, P. E., Sándor, K., Dániel, B., Foufelle, F., Ding, J., Li, X., Khorasanizadeh, S., & Osborne, T. F. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.07.025 · Cited by 78
Role of Glucocorticoids in Metabolic Dysfunction-Associated Steatotic Liver Disease
Pοlyzos, S. A., & Targher, G. (2024) · Current Obesity Reports · doi:10.1007/s13679-024-00556-1 · Cited by 82
“In line with these experimental findings, 11β-HSD1 mRNA expression was higher in the liver of patients with MASH than in control subjects [45].”
InfluentialDual-5α-Reductase Inhibition Promotes Hepatic Lipid Accumulation in Man
Hazlehurst, J. M., Oprescu, A. I., Nikolaou, N., Di Guida, R., Grinbergs, A. E. K., Davies, N. P., Flintham, R. B., Armstrong, M. J., Taylor, A. E., Hughes, B. A., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2928 · Cited by 71
Self-citationPοlyzos, S. A., Kountouras, J., Tsatsoulis, A. A., Zafeiriadou, E., Katsiki, E., Patsiaoura, K., Zavos, C., Anastasiadou, V., & Slavakis, A. (2013) · HORMONES · doi:10.1007/bf03401306 · Cited by 64
“Similarly to previous studies, serum cortisol levels were not different between NAFLD and control groups.(10,31) However, some,(31) but not all,(32) authors proposed that hepatic 11 -hydroxysteroid dehydrogenase type 1 (11 -HSD1), which converts cortisone to the active cortisol, is increased in NASH patients, thereby…”
ResultWei, X., Wu, D., Li, J., Wu, M., Li, Q., Che, Z., Cheng, X., Cheng, Q., Yin, F., Zhang, H., et al. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.08.010 · Cited by 54
5α-Reductase Type 2 Regulates Glucocorticoid Action and Metabolic Phenotype in Human Hepatocytes
Nasiri, M., Nikolaou, N., Parajes, S., Krone, N. P., Valsamakis, G., Mastorakos, G., Hughes, B., Taylor, A., Bujalska, I. J., Gathercole, L. L., et al. (2015) · Endocrinology · doi:10.1210/en.2015-1149 · Cited by 50
Self-citationJawad, M. Y., Meshkat, S., Tabassum, A., Mckenzie, A., Vincenzo, J. D. D., Guo, Z., Musavi, N. B., Phan, L., Ceban, F., Kwan, A. T. H., et al. (2022) · CNS Spectrums · doi:10.1017/s1092852922001043 · Cited by 54
Mallappa, A., Nella, A. A., Sinaii, N., Rao, H., Gounden, V., Perritt, A. F., Kumar, P., Ling, A., Liu, C., Soldin, S. J., et al. (2018) · Clinical Endocrinology · doi:10.1111/cen.13813 · Cited by 45
Zou, X., Ramachandran, P., Kendall, T. J., Pellicoro, A., Dorà, E., Aucott, R. L., Manwani, K., Man, T. Y., Chapman, K. E., Henderson, N. C., et al. (2018) · Hepatology · doi:10.1002/hep.29734 · Cited by 46
“In contrast, another study showed that in early stages of nonalcoholic fatty liver disease (NAFLD), with steatosis alone, hepatic 11bHSD1 activity is reduced, whereas progression to NASH was associated with increased 11bHSD1 levels.((11)) Importantly, 11bHSD1 inhibitors have been developed and shown to be moderately e…”
ResultSteroid metabolomic disease signature of nonsyndromic childhood obesity
Gawlik, A., Shmoish, M., Hartmann, M. F., Malecka-Tendera, E., Wudy, S. A., & Hochberg, Z. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-1754 · Cited by 36
“However, nonalcoholic fatty liver disease may also influence metabolism through multiple metabolic effects by nondetoxified metabolites (29).”
BackgroundShavakhi, M., Nourigheimasi, S., Dioso, E., Goutnik, M., Lucke-Wold, B. P., Khanzadeh, S., & Heidari, F. (2022) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2022/1554079 · Cited by 44
“[27] 11β-HSD1 serves as a primary regulator that catalyzes the reduction reaction of inactive cortisone to active cortisol.”
BackgroundInfluentialAlterations of Cortisol Metabolism in Human Disorders
White, P. C. (2018) · Hormone Research in Paediatrics · doi:10.1159/000485508 · Cited by 39
Nonalcoholic Fatty Liver Disease and Endocrine Axes—A Scoping Review
von Hafe, M., Borges‐Canha, M., Vale, C., Leite, A. R., Neves, J. S., Carvalho, D. M., & Leite-Moreira, A. F. (2022) · Metabolites · doi:10.3390/metabo12040298 · Cited by 37
Corona‐Pérez, A., Díaz‐Muñoz, M., Cuevas‐Romero, E., Luna-Moreno, D., Valente‐Godínez, H., Martínez, O. V., Martínez–Gómez, M., Rodríguez‐Antolín, J., & Nicolás‐Toledo, L. (2017) · Stress · doi:10.1080/10253890.2017.1381840 · Cited by 36
Association between Nonalcoholic Fatty Liver Disease and Endocrinopathies: Clinical Implications
Sîngeap, A.-M., Stanciu, C., Huiban, L., Muzica, C. M., Cuciureanu, T., Gîrleanu, I., Chiriac, S. A., Zenovia, S., Năstasă, R., Sfarti, C. V., et al. (2021) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2021/6678142 · Cited by 33
“GCs’ metabolism has an adaptive power since there are differences between uncomplicated steatosis and steatohepatitis; in simple steatosis, there is an increased clearance of cortisol as a protective mechanism trying to restrict lipid accumulation while, in steatohepatitis, the 11β-HSD1 has an increased activity in or…”
Sarafoglou, K., Merke, D. P., Reisch, N., der Grinten, H. L. C., Falhammar, H., & Auchus, R. J. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad134 · Cited by 35
Passos, E., Pereira, C., Gonçalves, I. O., Rocha‐Rodrigues, S., Silva, N., Guimarães, J. T., Neves, D., Ascensão, A. A. M. R., Magalhães, J., & Martins, M. J. (2014) · Life Sciences · doi:10.1016/j.lfs.2014.12.013 · Cited by 34
Factors impacting on the action of glucocorticoids in patients receiving glucocorticoid therapy
Dineen, R., Stewart, P. M., & Sherlock, M. (2019) · Clinical Endocrinology · doi:10.1111/cen.13837 · Cited by 30
Self-citationLutz, S. Z., Peter, A., Machicao, F., Lamprinou, A., Machann, J., Schick, F., Königsrainer, I., Königsrainer, A., Fritsche, A., Staiger, H., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2498 · Cited by 27
Moolla, A., de Boer, J., Pavlov, D., Amin, A., TAYLOR, A. E. R., Gilligan, L. C., Hughes, B. A., Ryan, J. D., Barnes, E. J., Hassan-Smith, Z. K., et al. (2020) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15710 · Cited by 27
Self-citationCrowley, R. K., Hughes, B., Gray, J., McCarthy, T., Hughes, S., Shackleton, C. H. L., Crabtree, N., Nightingale, P., Stewart, P. M., & Tomlinson, J. W. (2014) · European Journal of Endocrinology · doi:10.1530/eje-14-0256 · Cited by 26
Self-citationNikolaou, N., Hodson, L., & Tomlinson, J. (2021) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2021.105808 · Cited by 30
Self-citationBarrea, L., Verde, L., Camajani, E., Šojat, A. S., Marina, L., Savastano, S., Colao, A., Caprio, M., & Muscogiuri, G. (2023) · Journal of Endocrinological Investigation · doi:10.1007/s40618-023-02068-6 · Cited by 30
“Tissue-specific dysregulation of cortisol metabolism in human obesity and furthermore, excess liver fat increases glucocorticoid metabolite excretion in urine and can further decrease the hepatic 11β-HSD1 activity [22].”
BackgroundNikolaou, N., Gathercole, L., Kirkwood, L., Dunford, J. E., Hughes, B. A., Gilligan, L. C., Oppermann, U. C. T., Penning, T. M., Arlt, W., Hodson, L., et al. (2019) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2019.02.002 · Cited by 25
“In addition, changes in activity and expression of 11βHSDs and 5αRs have been linked to the development of metabolic diseases including NAFLD, T2DM and insulin resistance [12,30,31].”
BackgroundSelf-citationTeofilović, A., Veličković, N. A., Bursać, B. N., Djordjevic, A. D., Milutinović, D. V., Nestorović, N. M., & Matić, G. M. (2013) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2013.04.001 · Cited by 25
“[42], as well as by decreased insulin sensitivity [40], thus implying the complex role of 11βHSD1 in the liver metabolism.”
BackgroundInfluence of Plasma Cortisol and Other Laboratory Parameters on Nonalcoholic Fatty Liver Disease
Hubel, J., Schmidt, S. A., Mason, R., Haenle, M. M., Oeztuerk, S., Köenig, W., Boehm, B. O., Kratzer, W., Graeter, T., Flechtner‐Mors, M., et al. (2014) · Hormone and Metabolic Research · doi:10.1055/s-0034-1389982 · Cited by 24
“Following completion of the study, total cortisol concentrations of the until then deep-frozen serum samples were determined using the Cobas e411 testing unit (Roche) in samples that remained frozen until processing.”
Larner, D. P., Morgan, S., Gathercole, L., Doig, C. L., Guest, P., Weston, C. J., Hazeldine, J., Tomlinson, J., Stewart, P. M., & Lavery, G. G. (2016) · Endocrinology · doi:10.1210/en.2016-1357 · Cited by 24
“The enhanced inflammatory phenotype exhibited by 11 HSD1KO mice also endorses clinical data, whereby steatohepatitis was accompanied with an increase in 11 HSD1, suggesting a requirement for increased GC activity in inflamed livers (19).”
BackgroundSelf-citationZhang, S., Xu, Y., Zhang, S., Zhao, C., Feng, D., & Feng, X. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120379 · Cited by 21
Lü, H., Lei, X., Guo, S., Winkler, R., John, S., Kumar, D., Li, W., & Alnouti, Y. (2022) · Lipids in Health and Disease · doi:10.1186/s12944-022-01654-6 · Cited by 20
“Literature suggests that activation of GR in extrahepatic tissues worsens NAFLD, whereas hepatic GR may be protective in lipid metabolism during HFD intake [149–153].”
BackgroundInfluentialConfiguration of antibodies for assay of urinary cortisol in dogs influences analytic specificity
Zeugswetter, F. K., Neffe, F., Schwendenwein, I., Tichy, A., & Möstl, E. (2013) · Domestic Animal Endocrinology · doi:10.1016/j.domaniend.2013.06.003 · Cited by 20
“Increased urinary cortisol metabolites in the face of normal urinary cortisol concentrations have been reported in patients with obesity-related metabolic syndrome [16] and non–alcoholic fatty liver disease [17].”
BackgroundBini, J., Bhatt, S., Hillmer, A. T., Gallezot, J., Nabulsi, N., Pracitto, R., Labaree, D. C., Kapinos, M., Ropchan, J. R., Matuskey, D., et al. (2020) · Molecular Imaging and Biology · doi:10.1007/s11307-020-01490-z · Cited by 20
Woods, C. P., & Tomlinson, J. (2015) · Advances in experimental medicine and biology · doi:10.1007/978-1-4939-2895-8_16 · Cited by 20
“have described a switch in the expression of 11β (Beta)-HSD1 across the spectrum of liver disease from lower expression of 11β (Beta)-HSD1 in steatosis to higher levels of 11β (Beta)-HSD1 expression associated with steatohepatitis [ 74 ].”
BackgroundSelf-citationInflammatory liver diseases and susceptibility to sepsis
Lü, H. (2024) · Clinical Science · doi:10.1042/cs20230522 · Cited by 20
Lipid Hormones at the Intersection of Metabolic Imbalances and Endocrine Disorders
Dobre, M.-Z., Vîrgolici, B., & Cioarca-Nedelcu, R. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47070565 · Cited by 23
“In contrast, during steatohepatitis, 5 α -reductase levels decline and 11 β -HSD1 expression rises, leading to elevated hepatic cortisol concentrations [47,48].”
Diet-induced weight loss alters hepatic glucocorticoid metabolism in type 2 diabetes mellitus
Stomby, A., Otten, J., Ryberg, M., Andrew, R., Walker, B. R., & Olsson, T. (2020) · European Journal of Endocrinology · doi:10.1530/eje-19-0901 · Cited by 18
Milutinović, D. V., Teofilović, A., Veličković, N. A., Brkljačić, J. M., Jelača, S., Djordjevic, A. D., & Μacut, D. (2021) · Endocrine · doi:10.1007/s12020-020-02600-1 · Cited by 19
Maeyama, H., Hirasawa, T., Tahara, Y., Obata, C., Kasai, H., Moriishi, K., Mochizuki, K., & Kubota, T. (2015) · Journal of Developmental Origins of Health and Disease · doi:10.1017/s2040174415000100 · Cited by 17
Mallappa, A., Nella, A. A., Kumar, P., Brooks, K. M., Perritt, A. F., Ling, A., Liu, C.-Y., & Merke, D. P. (2017) · Journal of the Endocrine Society · doi:10.1210/js.2017-00215 · Cited by 16
“Changes in cortisol-cortisone metabolism in the liver, adipose tissue, and skeletal muscle have been implicated in the pathogenesis of nonalcoholic fatty liver disease, and tissue-specific dysregulation of glucocorticoid metabolism in the liver and fat may link insulin resistance and fatty liver with obesity [7, 8].”
BackgroundA genetic mouse model of lean-NAFLD unveils sexual dimorphism in the liver-heart axis
Burelle, C., Clapatiuc, V., Deschênes, S., Cuillerier, A., Loof, M. D., Higgins, M., Boël, H., Daneault, C., Chouinard, B., Clavet‐Lanthier, M., et al. (2024) · Communications Biology · doi:10.1038/s42003-024-06035-6 · Cited by 15
“Based on a study by Ahmed et al. 29 , there are two seemingly protective phases of altered hepatic cortisol meta-bolisminprogressiveNAFLD.”
Wang, W., She, F., Xie, L., Yan, W., Ouyang, J., Wang, B., Ma, H.-Y., Zang, L., & Mu, Y. (2016) · Chinese Medical Journal · doi:10.4103/0366-6999.181967 · Cited by 15
“To maintain normal circulating cortisol concentrations, the HPA axis was activated by a negative feedback pathway, which enhanced ACTH and ACTH‐dependent DHEAS production.[11] Therefore, it was reasonable that in our study, basal serum cortisol levels were similar between patients with and without NAFLD, and basal ser…”
BackgroundAssociations of Hair Cortisol Concentrations with General and Organ Fat Measures in Childhood
Vehmeijer, F. O. L., Santos, S., Gaillard, R., de Rijke, Y. B., Voortman, T., van den Akker, E. L. T., Felix, J. F., van Rossum, E. F. C., & Jaddoe, V. W. V. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa785 · Cited by 17
Metabolic-associated fatty liver disease and the role of hormones in its aetiopathogenesis
Suwała, S., & Junik, R. (2024) · Endokrynologia Polska · doi:10.5603/ep.99689 · Cited by 17
Vinodraj, K., Im, N. N., Rao, J., Mathai, P., Chandralekha, N., Nitasha, B., Rajesh, D., & Chethan, T. (2015) · Indian Journal of Pharmacology · doi:10.4103/0253-7613.153426 · Cited by 13
Narrative Review: Glucocorticoids in Alcoholic Hepatitis—Benefits, Side Effects, and Mechanisms
Lü, H. (2022) · Journal of Xenobiotics · doi:10.3390/jox12040019 · Cited by 13
“The literature suggests hepatic GR deficiency in non-alcoholic fatty liver disease and AH [38,39].”
Backgroundde Heide, L. J. M., de Boer, H. H. R., van Borren, M. M. G. J., Emous, M., Aarts, E. O., & de Boer, H. (2018) · Journal of the Endocrine Society · doi:10.1210/js.2018-00239 · Cited by 13
Steroid metabolomic signature of liver disease in nonsyndromic childhood obesity
Gawlik, A., Shmoish, M., Hartmann, M. F., Wudy, S. A., Olczak, Z., Gruszczyńska, K., & Hochberg, Z. (2019) · Endocrine Connections · doi:10.1530/ec-18-0536 · Cited by 12
Evidence for a role of sterol 27-hydroxylase in glucocorticoid metabolism in vivo
Vögeli, I., Jung, H. H., Dick, B., Erickson, S. K., Escher, R., Funder, J. W., Frey, F. J., & Escher, G. (2013) · Journal of Endocrinology · doi:10.1530/joe-13-0141 · Cited by 12
“In non-alcoholic fatty liver disease, one of the manifestations of the metabolic syndrome, increased clearance and decreased hepatic regeneration of cortisol have been proposed as protective mechanisms to decrease the local availability of glucocorticoids (Ahmed et al. 2012).”
BackgroundResultDried urine and salivary profiling for complete assessment of cortisol and cortisol metabolites
Newman, M. S., Curran, D. A., & Mayfield, B. P. (2020) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2020.100243 · Cited by 13
Kalra, S., Bhattacharya, S., & Rawal, P. (2021) · Medical Sciences · doi:10.3390/medsci9020039 · Cited by 14
López‐Amador, N., Nolasco-Hipólito, C., Jimeno, M. D. J. R., & Carvajal‐Zarrabal, O. (2017) · Clinical Investigation · doi:10.4172/clinical-investigation.1000107 · Cited by 11
“entail, such as portal hypertension and hepatocellular carcinoma [1,2] There are two major groups of fatty liver, either alcoholic or non-alcoholic [3-5].”
BackgroundSarcopenia in the setting of nonalcoholic fatty liver
Arrese, M. A., Cabello‐Verrugio, C., Arab, J. P., Francisco Barrera, M., Baudrand, R., Guarda, F. J., Gul, I., & Cabrera, D. (2022) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2021.16 · Cited by 10
The impact of cortisol in steatotic and non‐steatotic liver surgery
Cornide‐Petronio, M. E., Bujaldon, E., Mendes-Braz, M., León, C. G. A.-D., Jiménez‐Castro, M. B., Álvarez‐Mercado, A. I., Gracia‐Sancho, J., Rodés, J., & Peralta, C. (2017) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13156 · Cited by 11
“As in some chronic inflammatory conditions, such as non-alcoholic steatohepatitis, inflammatory bowel disease and colitis [12, 36], overexpression of 11b-HSD1 and reductase Fig.”
BackgroundSumińska, M., Podgórski, R., Fichna, P., & Fichna, M. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.759971 · Cited by 11
NASH in Nondiabetic Endocrine Disorders
Wang, T., Yang, W., Karakas, S. E., & Sarkar, S. (2018) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2018.0044 · Cited by 9
“44 Interestingly, only 20% of patients with Cushing’s disease (or nonfunctioning pituitary adenoma) who are on daily hydrocortisonehavehepaticsteatosis.”
Altered cortisol metabolism in individuals with HNF1A‐MODY
Juszczak, A., Gilligan, L. C., Hughes, B. A., Hassan-Smith, Z. K., McCarthy, M. I., Arlt, W., Tomlinson, J., & Owen, K. R. (2020) · Clinical Endocrinology · doi:10.1111/cen.14218 · Cited by 9
Self-citationShao, Q., Zhang, C. Y., Mu, J., Ji, J., Li, C., Ma, C., & Cheng, F. (2025) · Journal of Molecular Endocrinology · doi:10.1530/jme-25-0056 · Cited by 9
Liver impairment and medical management of Cushing syndrome and MACS
Minasyan, M., Suchy, W., Fedak, A., Gamrat-Żmuda, A., Hubalewska–Dydejczyk, A., Valassi, E., & Gilis‐Januszewska, A. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1660316 · Cited by 8
Xiao, W., Lu, M.-H., Rong, P., Zhang, H., Gong, J., Peng, Y., Gong, H., & Liu, Z. (2020) · Molecular Medicine Reports · doi:10.3892/mmr.2020.11423 · Cited by 14
“For example, Konopelska et al (37) reported that there was no association between hepatic 11β-HSd1 expression and the pathology of fatty liver or non‑alcoholic steatohepatitis (NASH) in humans, whereas Ahmed et al (38) suggested that in the early stages of nonalcoholic fatty liver disease (NAFLD), with steatosis alone…”
BackgroundYang, L., Wang, F., Liu, S., Xian, Z., Yang, S., Xu, Y., Shu, L., Yan, X., He, J., Li, X., et al. (2024) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2024.103068 · Cited by 8
Cataldi, M., Citro, V., Resnati, C., Manco, F., & Tarantino, G. (2021) · Advances in Therapy · doi:10.1007/s12325-021-01669-y · Cited by 8
Gligorovska, L., Teofilović, A., Milutinović, D. V., Miladinović, N., Kovačević, S., Veličković, N. A., & Djordjevic, A. D. (2021) · BioFactors · doi:10.1002/biof.1711 · Cited by 10
Neutrophils: tissue and circulating signatures of pediatric non-alcoholic fatty liver disease
Săsăran, M. O., Muntean, C., Lupu, A., & Lupu, V. V. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1336033 · Cited by 8
Wang, Y., Fahy, C., & Lü, H. (2024) · Liver Research · doi:10.1016/j.livres.2024.06.001 · Cited by 6
Naveed, S., Ahmed, S. M., Nageen, A., Ali, Z., Kumar, S., Zakir, H., & Ghazi, L. (2016) · The Professional Medical Journal · doi:10.29309/tpmj/2016.23.02.862 · Cited by 6
Associations of SRD5A1 gene variants and testosterone with dysglycemia: Henan Rural Cohort study
Liu, X., Wei, D., Jiang, J., Liu, X., Tu, R., Luo, Z., Wang, Y., Dong, X., Qiao, D., Shen, F., et al. (2019) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2019.11.011 · Cited by 7
Alteration in glucocorticoids secretion and metabolism in patients affected by cystic fibrosis
Podgórski, R., Sumińska, M., Rachel, M., Fichna, M., Fichna, P., & Mazur, A. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1074209 · Cited by 7
Glucocorticoid Regulation of Body Composition and Metabolism
Opata, A. A., Cheesman, K. C., & Geer, E. B. (2016) · Springer eBooks · doi:10.1007/978-3-319-45950-9_1 · Cited by 7
Sarkarova, M. R., & Maevskaya, M. V. (2022) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2022-16-7-60-68 · Cited by 7
Sofra, X. (2022) · Journal of Diabetes Metabolic Disorders & Control · doi:10.15406/jdmdc.2022.09.00235 · Cited by 5
Zatsepina, E. A., Samoilov, V. S., Volynkina, A. P., Stepanenko, A. V., & Novichikhina, E. E. (2023) · Problems of Endocrinology · doi:10.14341/probl13206 · Cited by 5
Mathai, P., Nayak, N., Rao, M., Bhat, G., Vinodraj, K., Chandralekha, N., Rajesh, D., & Chethan, T. (2015) · International Journal of Basic & Clinical Pharmacology · doi:10.5455/2319-2003.ijbcp20150209 · Cited by 4
Gao, B., Zhu, Y., Shen, W., Stärkel, P., & Schnabl, B. (2022) · Metabolites · doi:10.3390/metabo12111107 · Cited by 3
“Changes in cortisol metabolism were also observed in patients with non-alcoholic fatty liver disease [27].”
BackgroundChanges of androgen and corticosterone metabolites excretion and conversion in cystic fibrosis
Podgórski, R., Sumińska, M., Rachel, M., Pikuła, B., Fichna, P., Bidlingmaier, M., & Fichna, M. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1244127 · Cited by 3
“In contrast, liver function is often affected in CF, but the activity of SRD5A in nonalcoholic fatty liver disease was reported to be reduced (67).”
Dalhuisen, T., Grebe, H., Anglin, K., Lu, S., Goldberg, S. A., Kallás-Silva, L., Hauser, J., Conway, E., Ewing, M., Chen, J. Y., et al. (2024) · medRxiv · doi:10.1101/2024.11.07.24316777 · Cited by 3
“Document history of liver or kidney disease, which may directly impact cortisol secretion and/or metabolism 32,33,34,35 .”
BackgroundMiller, H., Harman, D., Aithal, G. P., Manousou, P., Cobbold, J., Parker, R., Sheridan, D. A., Newsome, P. N., Karpe, F., Neville, M., et al. (2024) · BMJ Open · doi:10.1136/bmjopen-2023-074918 · Cited by 2
“Through the recruitment of 310 participants with NAFLD, we will have 85% power to identify a difference in sensitivity between technologies of 12 percentage points (80% vs 92”
InfluentialSelf-citationCortisol Metabolism as a Regulator of the Tissue-Specific Glucocorticoid Action
Sbardella, E., & Tomlinson, J. (2016) · Springer eBooks · doi:10.1007/978-3-319-45950-9_14 · Cited by 3
Self-citationConstantinopoulos, P., Georgoulia, G., Theofanis, G., Antzoulas, A., Litsas, D., Papadopoulos, P. D., Liolis, E., Leventis, P., Kornaros, N., Leivaditis, V., et al. (2025) · Archives of Medical Science - Atherosclerotic Diseases · doi:10.5114/amsad/209847 · Cited by 1
“Via the portal circulation the increased FFA and cortisol reach the liver, where the glucocorticoids can promote steatosis by directly stimulating both hepatic de novo lipogenesis and FFA utilization [47].”
Ho, D., Won, H. Y., Kim, Y., & Lim, W. (2026) · Advances in experimental medicine and biology · doi:10.1007/978-981-95-6872-7_12 · Cited by 1
The long-term effects of effortless exercise on hormonal balance and health
Sofra, X. (2023) · Journal of Diabetes Metabolic Disorders & Control · doi:10.15406/jdmdc.2023.10.00258 · Cited by 2
Jiffri, E. H. (2018) · Current Research in Diabetes & Obesity Journal · doi:10.19080/crdoj.2018.07.555706
Sepehri, A., Jahromi, G. P., Shahbazi, A., Sahraei, H., Hatef, B., Meftahi, G. H., & Negah, S. S. (2022) · Acta Histochemica · doi:10.1016/j.acthis.2022.151960
Endocrinopathies in Nonalcoholic Fatty Liver Disease
Sîngeap, A.-M., & Huiban, L. (2023) · Springer eBooks · doi:10.1007/978-3-031-33548-8_16
Metadata
- Authors
- Ahmed, A., Rabbitt, E., Brady, T., Brown, C., Guest, P., Bujalska, I. J., Doig, C., Newsome, P. N., Hubscher, S., Elias, E., Adams, D. H., Tomlinson, J. W., & Stewart, P. M.
- Affiliations
- University of Birmingham (GB)
- University Hospitals Birmingham NHS Foundation Trust (GB)
- Corresponding author
- Stewart, Paul M.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2012-02-20
- Volume
- 7
- Issue
- 2
- Pages
- e29531
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3282715
- OpenAlex
- W2061954662
- Cited by
- 115
- References
- 46
- Citations by year
- 2026: 7 · 2025: 4 · 2024: 10 · 2023: 7 · 2022: 20 · 2021: 10 · 2020: 7 · 2019: 3 · 2018: 8 · 2017: 6 · 2016: 9 · 2015: 9 · 2014: 6 · 2013: 9
- FWCI
- 5.75
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
- Nottingham Trent University's Institutional Repository (Nottingham Trent Repository) (acceptedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion, other-oa)
- Funders
- Wellcome Trust (082809, 082809/Z/07/Z)
- National Institute for Health and Care Research (NF-SI-0508-10356)
- Medical Research Council
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Keywords
- non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, 11β-hydroxysteroid dehydrogenase type 1, 5α-reductase, 5beta-reductase, glucocorticoids, hepatic steatosis, liver cirrhosis, hepatic macrophages, liver inflammation, metabolic syndrome, Cushing's syndrome
- MeSH terms
- Adult, Fatty Liver, Humans, Hydrocortisone, Liver, Middle Aged, Models, Biological, Obesity, RNA, Messenger, Gene Expression Regulation, Enzymologic, Case-Control Studies, Disease Progression, 11-beta-Hydroxysteroid Dehydrogenase Type 1, Real-Time Polymerase Chain Reaction, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.